Study identifier:LAS-MD-CL26
ClinicalTrials.gov identifier:NCT00500318
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Effect of Inhaled Aclidinium Bromide (LAS34273) 200 ug on Exercise Endurance and Lung Hyperinflation in Patients with Moderate to Severe COPD
Pulmonary Disease, Chronic Obstructive
Phase 3
No
Aclidinium Bromide, Placebo
All
181
Interventional
40 Years +
Allocation: Randomized 
Endpoint Classification: None 
Intervention Model: Parallel Assignment 
Masking: Double Blind 
Primary Purpose: Treatment 
Verified 01 Nov 2016 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions | 
|---|---|
| Experimental: Aclidinium | Drug: Aclidinium Bromide  Aclidinium Bromide, 200μg. Once daily oral inhalation. | 
| Placebo Comparator: Placebo | Drug: Placebo  Dose matched placebo, once daily oral inhalation. |